Mr. Sapirstein brings over thirty years of pharmaceutical industry experience to Leading BioSciences. He currently serves as the CEO of ContraVir Pharmaceuticals, Inc. (traded on NASDAQ). After beginning his career in 1984 as a sales representative with Eli Lilly, he accepted a position at Hoffmann-LaRoche in 1987, where he served for almost a decade as part of its sales and marketing teams. He held a number of positions at Hoffmann-LaRoche, including Product Director and International Operations Manager, and was actively involved with numerous product launches including several antivirals. In 1996, he became the Director of International Marketing of the Infectious Disease Division at Bristol Myers Squibb (BMS). Mr. Sapirstein directed the international HIV product marketing strategy at BMS and was an integral part of the international development and launch of a number of infectious disease products while at BMS.
Mr. Sapirstein started his career in smaller biotech companies when he later joined Gilead Sciences, Inc. (GILD) in order to lead the Global Marketing team in its launch of Viread (tenofovir) In 2002, he accepted the position of Executive Vice President Metabolic and Endocrinology for Serono Laboratories before becoming the founding CEO of Tobira Therapeutics in 2006. In 2012, after several years in the infectious diseases space, Mr. Sapirstein became the CEO of Alliqua Therapeutics at Alliqua, Inc., where he helped lead the transformation of transdermal wound care and drug delivery technology into a premier wound care organization. James has been part of 23 product launches and has lead six global product launches. He has led several M&A transactions as well as leading many cross functional teams over his career. Mr. Sapirstein holds board positions on RespireRx Pharmaceuticals (RSPI), BioNJ and BIO. He has served on previous company boards which were later acquired.